Gabapentin Capsule
Product Images NDC 71335-1093

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

Illustration showing the formula to calculate creatinine clearance (CLCr) based on age, weight, serum creatinine level, and a correction factor for female patients (0.85).*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin, depicting a cyclohexane ring attached to an amino methyl group and an acetic acid group, corresponding to the active ingredient Gabapentin.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting the mean pain score over an 8-week period for placebo and Gabapentin 3600 mg/day groups. The x-axis shows weeks from baseline through week 8, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decrease in pain score over time, while placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10. Gabapentin groups show decreased pain scores over time compared to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing results from two studies. Study 1 shows 12% responders for placebo (PBO) and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance markers indicate p-values less than 0.01 and 0.001 for several treatments versus placebo.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing differences in percentage by daily dose of gabapentin (mg) across three studies labeled as study a, study b, and study c. The x-axis represents daily doses from 600 to 1800 mg, and the y-axis shows difference percentages from 2 to 22%. Different markers represent each study: black squares for study a, gray squares for study b, and white squares for study c.*

FDA Label Image

Label Image (Lbl713351093)

Gabapentin 300 mg capsule label by Bryant Ranch Prepack. The label states the product is comparable to Neurontin 300 mg capsule by Strides Pharma Science Limited. The package contains 90 capsules with prescription use only. It includes storage instructions, a warning about dizziness, and a barcode. The NDC on the label is 71335-1093-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.